antibody

DNA Methyltransferase 1 (DNMT1, DNMT, AIM, CXXC-type Zinc Finger Protein 9, CXXC9, DNA (Cytosine-5-)-methyltransferase 1, DNA MTase HsaI, FLJ16293, MCMT, M.HsaI, MGC104992)

D3931-614

100 ul

monoclonal

domestic rabbit

nonconjugated

10E19(D63A6)

DNA Methyltransferase 1 (DNMT1, DNMT, AIM, CXXC-type Zinc Finger Protein 9, CXXC9, DNA (Cytosine-5-)-methyltransferase 1, DNA MTase HsaI, FLJ16293, MCMT, M.HsaI, MGC104992)

rabbit

Mab

Antibodies

100 ul

10E19(D63A6)

IgG

Methylation of DNA at cytosine residues in mammalian cells is a heritable, epigenetic modification that is critical for proper regulation of gene expression, genomic imprinting and development (1,2). Three families of mammalian DNA methyltransferases have been identified: DNMT1, DNMT2 and DNMT3 (1,2). DNMT1 is constitutively expressed in proliferating cells and functions as a maintenance methyltransferase, transferring proper methylation patterns to newly synthesized DNA during replication. DNMT3A and DNMT3B are strongly expressed in embryonic stem cells with reduced expression in adult somatic tissues. DNMT3A and DNMT3B function as de novo methyltransferases that methylate previously unmethylated regions of DNA. DNMT2 is expressed at low levels in adult somatic tissues and its inactivation affects neither de novo nor maintenance DNA methylation. DNMT1, DNMT3A and DNMT3B together form a protein complex that interacts with histone deacetylases (HDAC1, HDAC2, Sin3A), transcriptional repressor proteins (RB, TAZ-1) and heterochromatin proteins (HP1, SUV39H1), to maintain proper levels of DNA methylation and facilitate gene silencing (3-8). Improper DNA methylation contributes to diseased states such as cancer (1,2). Hypermethylation of promoter CpG islands within tumor suppressor genes correlates with gene silencing and the development of cancer. In addition, hypomethylation of bulk genomic DNA correlates with and may contribute to the onset of cancer. DNMT1, DNMT3A and DNMT3B are over-expressed in many cancers, including acute and chronic myelogenous leukemias, in addition to colon, breast and stomach carcinomas (9-12). Applications: Suitable for use in Western Blot, Flow Cytometry and Immunofluorescence/Immunofluorescence. Other applications not tested. Recommended Dilution: Western Blot: 1:1000, incubate membrane with diluted primary antibody in 5% nonfat dry milk, 1X TBS, 0.1% Tween-20 at 4°C with gentle shaking, overnight. Flow Cytometry: 1:50 Immunofluorescence (IC): 1:100 Optimal dilutions to be determined by the researcher. Storage and Stability: May be stored at 4°C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20°C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Hu Mk Mo Rt

Synthetic peptide derived from the sequence of human DNMT1 protein. Species Sequence Homology: bovine, canine, guinea pig, equine, and hamster.

Recongnizes endogenous levels of human total DNMT1 protein. Species crossreactivity: mouse, rat, and monkey.

Purified

Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol.

Not determined

Product Type: Mab Isotype: IgG Clone No: 10E19(D63A6) Host: rabbit Source: human Concentration: Not determined Form: Supplied as a liquid in 10mM sodium HEPES, pH 7.5, 150mM sodium chloride, 0.1mg/ml BSA, 0.02% sodium azide, 50% glycerol. Purity: Purified Immunogen: Synthetic peptide derived from the sequence of human DNMT1 protein. Species Sequence Homology: bovine, canine, guinea pig, equine, and hamster. Specificity: Recongnizes endogenous levels of human total DNMT1 protein. Species crossreactivity: mouse, rat, and monkey. Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications without the expressed written authorization of United States Biological.

FC IC IF WB

-20°C

1. Hermann, A. et al. (2004) Cell. Mol. Life Sci. 61, 2571-2587, 2. Turek-Plewa, J. and Jagodzinski, P.P. (2005) Cell. Mol. Biol. Lett. 10, 631-647, 3. Kim, G.D. et al. (2002) EMBO J. 21, 4183-4195, 4. Fuks, F. et al. (2001) EMBO J. 20, 2536-2544, 5. Geiman, T.M. et al. (2004) Biochem. Biophys. Res. Commun. 318, 544-555, 6. Rountree, M.R. et al. (2000) Nat. Genet. 25, 269-277, 7. Pradhan, S. and Kim, G.D. (2002) EMBO J. 21, 779-788, 8. Fuks, F. et al. (2003) Nucleic Acids Res. 31, 2305-2312, 9. Mizuno, S. et al. (2001) Blood 97, 1172-1179, 10. Robertson, K.D. et al. (1999) Nucleic Acids Res. 27, 2291-2298, 11. Xie, S. et al. (1999) Gene 236, 87-95, 12. Kanai, Y. et al. (2001) Int. J. Cancer 91, 205-212.

https://usbio-images.r.worldssl.net/prodimages/48/D3931-614_1.jpg